ImmunoACT has a portfolio of CAR-T therapy assets under various development stages for the treatment of multiple autoimmune diseases and oncology indications.
Strides Pharma Science has reported consolidated financial results for the period ended September 30, 2021
Expertise in exosomes isolation and characterization will drive innovation in this field
GlaxoSmithKline Pharmaceuticals Limited has reported consolidated financial results for the period ended September 30, 2021
_256_384.jpg)
Both parties are expected to invest a total of US $ 1 million to establish the brand
It is the first company to launch Remogliflozin, Vildagliptin and Metformin combination
Key takeaways of recent quarter & conference call highlights
Key takeaways of recent quarter & conference call highlights
The quarter also saw continued investment in new technologies and the successful implementation of several digitization and automation projects across operations
Ipsen obtains an exclusive license to develop, manufacture and commercialize a pre-clinical stage METTL3-inhibitor programme
Subscribe To Our Newsletter & Stay Updated
